This finding further strengthened the notion that ER+ and ER- breast cancer should be handled as two separate entities when evaluating gene expression data, as has previously been stated by authors in analyses of gene expression profiles associated with distant metastases [14,24,40]. The gene discussed is ESR1; the disease is breast cancer.